Global Molecular Point-of-Care Testing Market Growth (Status and Outlook) 2025-2031

The global Molecular Point-of-Care Testing market size is predicted to grow from US$ 7918 million in 2025 to US$ 10540 million in 2031; it is expected to grow at a CAGR of 4.9% from 2025 to 2031.

Molecular point-of-care (POC) testing is a type of diagnostic testing that uses nucleic acid amplification techniques such as polymerase chain reaction (PCR) to rapidly detect the presence of specific genetic material, such as DNA or RNA, directly in patient samples.

The global molecular point-of-care testing (POCT) market refers to the market for diagnostic tests that can be performed at or near the point of patient care, providing rapid and accurate results for a wide range of diseases and conditions. Molecular POCT involves the use of molecular diagnostic techniques, such as polymerase chain reaction (PCR) and nucleic acid amplification tests (NAATs), to detect and identify specific genetic material or biomarkers associated with diseases or infections.

Here are some key factors influencing the growth of the global molecular POCT market:

Increasing demand for rapid and accurate diagnostic testing: The need for rapid and accurate diagnostic testing is driving the growth of the molecular POCT market. Molecular POCT offers advantages such as rapid turnaround time, portability, and the ability to provide accurate results at the point of care, eliminating the need for sample transportation to centralized laboratories. This is particularly beneficial in emergency and critical care settings, where timely diagnosis is crucial for effective patient management.

Technological advancements in molecular diagnostics: Molecular diagnostic technologies have witnessed significant advancements in recent years, enabling the development of portable, user-friendly, and easy-to-operate molecular POCT devices. These devices offer rapid and reliable results, making them suitable for use in various healthcare settings, including hospitals, clinics, ambulatory care centers, and remote or resource-limited areas. Technological advancements continue to drive the growth of the molecular POCT market.

Rising prevalence of infectious diseases: The global burden of infectious diseases, such as respiratory infections, sexually transmitted infections (STIs), and gastrointestinal infections, remains significant. Molecular POCT plays a crucial role in the rapid detection and identification of pathogens responsible for these infections. The increasing prevalence of infectious diseases, coupled with the need for early diagnosis and treatment, is boosting the demand for molecular POCT solutions.

Growing focus on personalized medicine: Personalized medicine aims to tailor medical treatments to individual patients based on their genetic makeup, lifestyle, and other factors. Molecular POCT plays a vital role in enabling personalized medicine by providing rapid and accurate genetic testing at the point of care. These tests help identify genetic variations, mutations, or biomarkers that can guide treatment decisions and improve patient outcomes. The growing focus on personalized medicine is driving the adoption of molecular POCT.

COVID-19 pandemic impact: The ongoing COVID-19 pandemic has significantly accelerated the demand for molecular POCT. Rapid and accurate testing for SARS-CoV-2, the virus responsible for COVID-19, has been crucial in controlling the spread of the disease and managing patient care effectively. Molecular POCT devices, such as rapid antigen tests and molecular NAATs, have been widely used for COVID-19 testing in various healthcare settings.

The global molecular POCT market can be segmented based on technology (PCR, NAATs, hybridization, and others), application (infectious diseases, oncology, genetics, and others), end-user (hospitals, clinics, ambulatory care centers, research institutes, and others), and geography (North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa).

In summary, the global molecular POCT market is driven by the increasing demand for rapid and accurate diagnostic testing, technological advancements in molecular diagnostics, the rising prevalence of infectious diseases, the growing focus on personalized medicine, and the impact of the COVID-19 pandemic. Molecular POCT offers the advantage of providing rapid and accurate results at the point of care, enabling timely and appropriate patient management. The market is expected to witness significant growth as the demand for portable and user-friendly molecular diagnostic solutions continues to rise.

LPI (LP Information)' newest research report, the “Molecular Point-of-Care Testing Industry Forecast” looks at past sales and reviews total world Molecular Point-of-Care Testing sales in 2024, providing a comprehensive analysis by region and market sector of projected Molecular Point-of-Care Testing sales for 2025 through 2031. With Molecular Point-of-Care Testing sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Molecular Point-of-Care Testing industry.

This Insight Report provides a comprehensive analysis of the global Molecular Point-of-Care Testing landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Molecular Point-of-Care Testing portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Molecular Point-of-Care Testing market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Molecular Point-of-Care Testing and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Molecular Point-of-Care Testing.

This report presents a comprehensive overview, market shares, and growth opportunities of Molecular Point-of-Care Testing market by product type, application, key players and key regions and countries.

Segmentation by Type:

Polymerase Chain Reaction (PCR)

Loop-mediated Isothermal Amplification (LAMP)

Nucleic Acid Sequence-based Amplification (NASBA)

Segmentation by Application:

Infectious Diseases

Genetic Disorders

Pregnancy Testing

Diagnosis of Cancer

Pharmacogenomics

This report also splits the market by region:

Americas

United States

Canada

Mexico

Brazil

APAC

China

Japan

Korea

Southeast Asia

India

Australia

Europe

Germany

France

UK

Italy

Russia

Middle East & Africa

Egypt

South Africa

Israel

Turkey

GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.

Roche Molecular Diagnostics

Roche Diagnostics

Abbott Laboratories

Danaher Corporation

bioMérieux, Inc.

Hologic, Inc.

Meridian Bioscience, Inc.

Saw Diagnostics

Siemens Healthineer

Sona Nanotech

T2 Biosystems

Talis Biomedical

Thermo Fisher Scientific Inc.

Veramarx

XCR Diagnostics

Zhejiang Orient Gene Biotech

Please note: The report will take approximately 2 business days to prepare and deliver.